Noctrix Health

A REVOLUTION in
wearable therapeutics

Developing clinically validated wearable therapeutics as true alternatives to pharmaceuticals for the management of chronic neurological disorders.

Explore a revolutionary wearable therapy for treating Restless Legs Syndrome (RLS).

The Unmet Need

Restless Legs Syndrome is a common sleep condition that can cause intense discomfort, resulting in an uncontrollable urge to move the legs and an inability to fall and stay asleep.

1 in 10

U.S. adults are affected
by RLS1

8 million

Americans experience symptoms more than 3 times per week1

#2 sleep disorder

RLS is the second most common sleep disorder in the US1

Limited

alternatives to pharmaceutical treatments2

1 in 10

U.S. adults are affected
by RLS1

8 million

Americans experience symptoms more than 3 times per week1

#2 Sleep Disorder

RLS is the second most common sleep disorder in the US1

8 million

alternatives to pharmaceutical treatments2

50%-70% of people with RLS on the leading prescription drug therapy still experience worsening symptoms.

1. Lipford MC, Silber MH. Sleep Med. 2012;13(10):1280-1285. 2. Silver N, et al. Sleep Med. 2011;12(5):440-444.

Discover the first and only drug-free wearable therapy clinically-proven
to reduce symptoms of RLS.

PR Newswire

Noctrix Health announces publication of landmark results from randomized clinical trial and long-term extension study of its revolutionary...

PLEASANTON, Calif., July 26, 2023 /PRNewswire/ — Noctrix Health, Inc. announced a double feature in the renowned peer-reviewed journal, Sleep, showcasing the outcomes of two major clinical trials that assessed TOMAC therapy

PR Newswire

Noctrix Health announces successful randomized controlled trial (RCT) outcomes and FDA Marketing Authorization for its Breakthrough Tonic Motor Activation (TOMAC) Restless Legs Syndrome (RLS) Therapy

PLEASANTON, Calif., April 19, 2023 /PRNewswire/ — Noctrix Health announced that the U.S. Food and Drug Administration (FDA) has granted its De Novo request for the NTX100 Tonic Motor Activation (TOMAC)

PR Newswire

Noctrix Health Announces Enrollment of First Patient in The RESTFUL Study and Publication of Positive Pilot Study Results

PLEASANTON, Calif., May 25, 2021 /PRNewswire/ — Noctrix Health, Inc. today announced that the first patient has been enrolled in a multi-center, rand

PR Newswire

Noctrix Health granted FDA Breakthrough Device Designation for wearable Restless Legs Syndrome Therapy

SAN FRANCISCO, June 2, 2020 /PRNewswire/ — Noctrix Health, Inc., a privately held medical device company announced today that the US Food and Drug Ad

PR Newswire

Noctrix Health, Inc. Completes $17M Million Series B Financing

SAN FRANCISCO, Jan. 11, 2021 /PRNewswire/ — Noctrix Health, Inc., a private medical device company, today announced it has completed a Series B finan

A REVOLUTION in
wearable therapeutics

The Unmet Need

1 in 10

8 million

#2 sleep disorder

Limited

1 in 10

8 million

#2 Sleep Disorder

8 million

Recent News

PR Newswire

Noctrix Health announces publication of landmark results from randomized clinical trial and long-term extension study of its revolutionary...

PR Newswire

Noctrix Health announces successful randomized controlled trial (RCT) outcomes and FDA Marketing Authorization for its Breakthrough Tonic Motor Activation (TOMAC) Restless Legs Syndrome (RLS) Therapy

PR Newswire

Noctrix Health Announces Enrollment of First Patient in The RESTFUL Study and Publication of Positive Pilot Study Results

PR Newswire

Noctrix Health granted FDA Breakthrough Device Designation for wearable Restless Legs Syndrome Therapy

PR Newswire

Noctrix Health, Inc. Completes $17M Million Series B Financing

Career Opportunities

Let’s connect!

A REVOLUTION in wearable therapeutics

The Unmet Need

1 in 10

8 million

#2 sleep disorder

Limited

1 in 10

8 million

#2 Sleep Disorder

8 million

Recent News

PR Newswire

Noctrix Health announces publication of landmark results from randomized clinical trial and long-term extension study of its revolutionary...

PR Newswire

Noctrix Health announces successful randomized controlled trial (RCT) outcomes and FDA Marketing Authorization for its Breakthrough Tonic Motor Activation (TOMAC) Restless Legs Syndrome (RLS) Therapy

PR Newswire

Noctrix Health Announces Enrollment of First Patient in The RESTFUL Study and Publication of Positive Pilot Study Results

PR Newswire

Noctrix Health granted FDA Breakthrough Device Designation for wearable Restless Legs Syndrome Therapy

PR Newswire

Noctrix Health, Inc. Completes $17M Million Series B Financing

Career Opportunities

Let’s connect!

A REVOLUTION in
wearable therapeutics